Nektar Therapeutics
NKTR
153 hedge funds and large institutions have $1.39B invested in Nektar Therapeutics in 2015 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 65 increasing their positions, 40 reducing their positions, and 35 closing their positions.
73% more call options, than puts
Call options by funds: $10.4M | Put options by funds: $6.04M
63% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 40
6% less funds holding
Funds holding: 163 → 153 (-10)
25% less capital invested
Capital invested by funds: $1.86B → $1.39B (-$470M)
26% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 35
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$24.7M |
| 2 |
Primecap Management
Pasadena,
California
|
+$18.2M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$17.7M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$13.2M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$17.7M |
| 2 |
Bank of New York Mellon
New York
|
-$13.1M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.1M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$6.74M |
| 5 |
PC
PointState Capital
New York
|
-$5.48M |
NKTR Hedge Fund Activity: Q1 2015 in Review
153 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2015, worth a combined $1.39B — down 25% from $1.86B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of NKTR and 26 opened new positions — a net loss of 9 holders — while 40 trimmed existing stakes and 65 added.
The largest buyer was OppenheimerFunds, adding an estimated $24.7M. The largest seller was Granahan Investment Management, cutting an estimated $17.7M.
- 153 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2015, down from 163 in Q4 2014.
- Funds reported $1.39B of Nektar Therapeutics stock for Q1 2015, down 25% quarter-over-quarter.
- 26 funds opened new Nektar Therapeutics positions in Q1 2015 and 35 closed out, a net change of -9 holders.
- The largest Nektar Therapeutics buyer in Q1 2015 was OppenheimerFunds, an estimated $24.7M added.
- The largest Nektar Therapeutics seller in Q1 2015 was Granahan Investment Management, an estimated $17.7M sold.
Based on aggregated 13F filings for Q1 2015.